Fig. 2From: Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registryTime-to-event analyses, from registry inclusion (pirfenidone-treated population), for patients who experienced (a) ≥ 10% absolute decline in percent predicted FVC and (b) ≥ 15% absolute decline in percent predicted DLco. DLco carbon monoxide diffusing capacity, FVC forced vital capacityBack to article page